Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Michael Lichter

Dermatology Nashua, NH Medical Doctor

NPI 1962572305 CMS profile 316291

505 W Hollis St, Nashua, NH 03062

Open in the dashboard

General payments

$53,479

511 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Michael Lichter of Nashua, NH is reported in the CMS Open Payments database as having received $53,479 across 511 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $12,913 142
2021 General $8,438 146
2020 General $6,685 96
2019 General $25,443 127

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Lichter
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Michael Lichter were reported at $0. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Michael Lichter Dermatology median Middle half National median
2019 $25,443 $454 $129–$1,240 $163
2020 $6,685 $235 $81–$756 $114
2021 $8,438 $377 $108–$1,108 $132
2022 $12,913 $514 $143–$1,391 $149
2023 $0 $607 $159–$1,674 $160
2024 $0 $751 $204–$1,903 $164
2025 $0 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. AbbVie, Inc. $45,820 152 payments
  2. LEO Pharma Inc. $1,554 80 payments
  3. Amgen Inc. $1,049 43 payments
  4. Janssen Biotech, Inc. $1,044 45 payments
  5. Novartis Pharmaceuticals Corporation $868 53 payments
  6. Sun Pharmaceutical Industries Inc. $436 20 payments
  7. Genzyme Corporation $416 20 payments
  8. UCB, Inc. $375 21 payments
  9. Sanofi-Aventis U.S. LLC $309 4 payments
  10. Lilly USA, LLC $298 13 payments
  11. Other $1,310 60 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $40,100 22 payments
  2. Food and Beverage $11,013 469 payments
  3. Travel and Lodging $2,208 16 payments
  4. Education $158 4 payments
Products named General payments · program years 2019–2022
  1. SKYRIZI $30,640 85 payments
  2. HUMIRA $14,403 69 payments
  3. RINVOQ $2,473 13 payments
  4. Otezla $1,049 43 payments
  5. ENSTILAR $969 52 payments
  6. TREMFYA $935 27 payments
  7. COSENTYX $613 39 payments
  8. ADBRY $559 27 payments
  9. DUPIXENT $415 12 payments
  10. Cimzia $375 21 payments
  11. Other $3,870 222 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

511 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New Hampshire

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record